Year: 2020
Type: article
Institutions: Brigham and Women's Hospital, Harvard University, Tohoku University, Thrombolysis in Myocardial Infarction Study Group, Universidade de São Paulo, Hospital Israelita Albert Einstein, Vienna General Hospital, Medical University of Vienna, Amgen (United States), The University of Sydney, National Health and Medical Research Council
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Keywords: PCSK9 inhibitors, coronary revascularization, complex percutaneous coronary intervention, coronary artery bypass grafting, multivessel PCI, bifurcation lesions, FOURIER trial, plaque regression, statin therapy, coronary artery disease, LDL cholesterol lowering, cardiovascular risk reduction, procedural characteristics
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Brigham and Women's Hospital, Intarcia Therapeutics, Amarin Corporation, Medicines Company, Mylan, Zora Biosciences, Bayer HealthCare, Deutsche Forschungsgemeinschaft, Daiichi-Sankyo, Eisai, Ministério da Saúde, Servier, Fundação Lemann, Esperion Therapeutics, Abbott Vascular, Japan Society for the Promotion of Science
OpenAlex ID: W3101397443
